Previous close | 0.7000 |
Open | 0.7000 |
Bid | 0.0000 |
Ask | 0.6000 |
Strike | 19.00 |
Expiry date | 2024-07-19 |
Day's range | 0.7000 - 0.7000 |
Contract range | N/A |
Volume | |
Open interest | 41 |
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.